What is the name of the surgical-specific generative AI developed by Direava Inc.?

Direava Inc. has developed Japan's first surgical-specific generative AI, referred to as Surgical VLM.

What is the primary function of this new surgical AI compared to conventional generative AI in surgery?

Unlike conventional generative AI limited to image recognition, this surgical AI understands the surgical situation and can engage in advanced dialogue with surgeons, acting like a 'doctor's brain'.

When and where was a demonstration test of this surgical AI conducted?

A demonstration test was conducted on February 20, 2026, during an actual gastric cancer surgery at Keio University Hospital.

What were the key criteria used to confirm the usefulness of the surgical AI during the demonstration test?

The usefulness was confirmed by meeting required standards for medical education, specifically anatomical accuracy, clinical utility, and textual fluency.

What are Direava Inc.'s future plans regarding this surgical-specific generative AI?

Direava Inc. is preparing for commercialization with a service launch planned by 2026 and will conduct further demonstrations for surgeries beyond gastric cancer.

AI News NQ Analysis

Developed a Surgical-Specific Generative AI that Brings "Intelligence" to the Operating Room

NQ Score 56/100

Key facts

Developed a Surgical-Specific Generative AI that Brings "Intelligence" to the Operating Room
Direava has successfully developed and demonstrated a generative AI that understands and interacts with surgical procedures in real-time.
Date: Sun Mar 29 2026 21:54:53 GMT+0900 (Japan Standard Time)

Direct answer

Direava has successfully developed and demonstrated a generative AI that understands and interacts with surgical procedures in real-time.

Citation: Developed a Surgical-Specific Generative AI that Brings "Intelligence" to the Operating Room (Sun Mar 29 2026 21:54:53 GMT+0900 (Japan Standard Time)), PR TIMES
Source: PR TIMES
Date: Sun Mar 29 2026 21:54:53 GMT+0900 (Japan Standard Time)

AI analysis data is not yet available.

Frequently Asked Questions

Q: What is the name of the surgical-specific generative AI developed by Direava Inc.?: A: Direava Inc. has developed Japan's first surgical-specific generative AI, referred to as Surgical VLM.
Q: What is the primary function of this new surgical AI compared to conventional generative AI in surgery?: A: Unlike conventional generative AI limited to image recognition, this surgical AI understands the surgical situation and can engage in advanced dialogue with surgeons, acting like a 'doctor's brain'.
Q: When and where was a demonstration test of this surgical AI conducted?: A: A demonstration test was conducted on February 20, 2026, during an actual gastric cancer surgery at Keio University Hospital.
Q: What were the key criteria used to confirm the usefulness of the surgical AI during the demonstration test?: A: The usefulness was confirmed by meeting required standards for medical education, specifically anatomical accuracy, clinical utility, and textual fluency.
Q: What are Direava Inc.'s future plans regarding this surgical-specific generative AI?: A: Direava Inc. is preparing for commercialization with a service launch planned by 2026 and will conduct further demonstrations for surgeries beyond gastric cancer.